FINHUB Insights

LLY · Q2 FY25 · Apr 1 – Jun 30, 2025

Eli Lilly Q2 FY25: where the revenue came from and where it went

Eli Lilly Q2 FY25: revenue $15.6B (+38% year over year). Net profit $5.7B. Largest cohort Mounjaro $5.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 7, 2025 10-Q
Sankey diagram of Eli Lilly's income statement for Q2 FY25: revenue of $15.6 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$15.6B +38% year over year
Gross profit$13.1B 84% margin
Operating profit$6.9B 44% margin
Net profit$5.7B 36% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 15.6 100% +38%
Mounjaro 5.2 33% +68%
Zepbound 3.4 22% +172%
Other 1.6 10%
Verzenio 1.5 10% +12%
Trulicity 1.1 7% −12%
Other Cardiometabolic Health 1 6% −16%
Other Oncology 0.9 6% +12%
Taltz 0.8 5% +3%
Cost of revenue−2.415%
Gross profit13.184% margin+3pp
SG&A−2.818%−1pp
Other−3.522%+0pp
Operating profit6.944% margin+11pp
Tax−1.1
Interest & other costs−0.1
Net profit5.736%+10pp
Filing on EDGAR More quarters of LLY

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters